630123-60-3

Upstream product

• 16874-12-7 Tyr(tBu) 
• 630123-58-9 N-(2-[N',N'-diethylamino]-5-nitropyrimidin-4-yl)-4'-(pyrrolidin-1-ylcarbonyloxy)-L-phenylalanine tert-butyl ester 

Downstream Products

• 933825-34-4 N-[2-diethylamino-5-{N-trifluoroacetylamino}pyrimidin-4-yl]-L-4'-{(pyrrolidin-1-yl)carbonyloxy}phenylalanine tert-butyl ester 
• 947739-48-2 (S)-4-(3-tert-butoxy-2-(2-(diethylamino)-5-(N-(methylsulfonyl)-methylsulfonamido)pyrimidin-4-ylamino)-3-oxopropyl)phenyl pyrrolidine-1-carboxylate 
• 947739-43-7 (S)-4-(3-tert-butoxy-2-(2-(diethylamino)-5-(isopropylamino)pyrimidin-4-ylamino)-3-oxo-propyl)phenyl pyrrolidine-1-carboxylate 
• 947739-49-3 (S)-4-(3-tert-butoxy-2-(2-(diethylamino)-5-(methylsulfonamido)-pyrimidin-4-ylamino)-3-oxopropyl)phenyl pyrrolidine-1-carboxylate 
• 1447308-37-3 C₂₇H₄₀N₆O₄ 
• 1447308-38-4 C₃₄H₄₆N₆O₄ 
• 1447308-14-6 C₃₅H₄₅FN₆O₅ 
• 1447308-15-7 C₃₅H₄₅FN₆O₅ 
• 1447308-16-8 C₃₂H₄₃N₇O₅S 
• 1447308-17-9 C₃₄H₄₅N₇O₅ 
• 1447308-18-0 C₃₃H₅₁N₇O₅ 

Relevant academic research and scientific papers

Arylsulfonamide pyrimidines as VLA-4 antagonists

A series of (S)-2-(2-(diethylamino)-5-(N-alkyl-N-sulfonamido)pyrimidin-4- ylamino)-3-(4-(carbamoyloxy)phenyl)propanoic acid is discovered as orally available VLA-4 antagonists. Representative compounds 11b and 11p showed efficacy in multiple in vivo anima

PYRIMIDINYL AMIDE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4

Disclosed are compounds which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a human or animal subject

CARBAMATE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4

Disclosed are compounds which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis (Formula I).

PYRIMIDINYL SULFONAMIDE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4

Disclosed are compounds, which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and. in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a human or animal subjec

HETEROCYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY α4 INTEGRINS

Disclosed are compounds which bind α4 integrins, preferably VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by α4 integrins, preferably VLA-4. Such compounds are useful in the treatment of